Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease Compared With Alglucosidase Alfa/Placebo

Next Previous
Trial Profile

A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease Compared With Alglucosidase Alfa/Placebo

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cipaglucosidase alfa (Primary) ; Miglustat (Primary) ; Alglucosidase alfa
  • Indications Glycogen storage disease type II
  • Focus Registrational; Therapeutic Use
  • Acronyms PROPEL
  • Sponsors Amicus Therapeutics

Most Recent Events

  • 18 Apr 2024 Results assessing Effect Size Analysis of Cipaglucosidase Alfa Plus Miglustat Versus Alglucosidase Alfa in ERT-experienced Adults with Late-onset Pompe Disease presented at the 76th Annual Meeting of the American Academy of Neurology 2024
  • 01 Feb 2024 According to an Amicus Therapeutics media release, data from this study will be presented at the 20th Annual WORLDSymposium™ 2024, being held February 4-9, 2024 in San Diego, CA.
  • 28 Sep 2023 According to an Amicus Therapeutics media release, announced that the U.S. Food and Drug Administration (FDA) has approved Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules for adults living with late-onset Pompe disease (LOPD).The FDA approval was based on clinical data observed from this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top